NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

免疫治療劑:全球市場

Immunotherapy Drugs: Global Markets

出版商 BCC Research 商品編碼 996380
出版日期 內容資訊 英文 143 Pages
訂單完成後即時交付
價格
免疫治療劑:全球市場 Immunotherapy Drugs: Global Markets
出版日期: 2021年03月18日內容資訊: 英文 143 Pages
簡介

全球免疫治療藥物市場將從2020年的1398億美元增長到2025年的2044億美元,從2020年到2025年的複合年增長率(CAGR)為7.9%。

免疫治療性單克隆抗體產品市場的規模預計將從2020年的1132億美元增長到2025年的1533億美元,從2020年到2025年的複合年增長率為6.3%。

免疫治療檢查點抑制劑產品的市場規模將從2020年的26□□3億美元增長到2025年的509億美元,從2020年到2025年的複合年增長率為14.1%。

本報告提供了對全球免疫治療藥物市場的全面調查,其中包括2019年至2020年的數據,2022年的估計值以及對2025年之前的年均複合增長率(CAGR)的預測。用於分析全球市場趨勢,評估當前市場規模和預測,分析新產品管道,監管方案以及對影響市場增長,免疫力的驅動因素,挑戰和機遇的深入分析療法描述,組合免疫療法以及關於如何靶向細胞適應性免疫療法的討論,市場份額分析行業主要參與者,他們的技術優勢和劣勢以及創新營銷,它提供了有關實踐等方面的討論。

目錄

第1章簡介

  • 調查目的/目的
  • 報告範圍
  • 調查方法
  • 市場規模估計
  • 來源
  • 初步調查
  • 二次調查
  • 地理細分
  • 分析師職業
  • 密件抄送自定義調查
  • BCC研究相關報告

第2章摘要和重點

第3章市場和技術背景

  • 免疫療法
  • 用於聯合免疫療法
  • 專注於細胞適應性免疫
  • 微調與增強癌症免疫力
  • 早期與晚期癌症免疫治療
  • 個性化醫學範例
  • 臨床上重要的癌症類型
  • 肺癌
  • 乳腺癌
  • 大腸癌
  • 胃癌
  • 白血病
  • 癌症免疫療法的未來
  • 傳染病
  • 自身免疫性疾病的免疫療法
  • 傳染病的免疫療法
  • 用於治療自身免疫性疾病的生物製藥
  • 自身免疫性疾病治療的趨勢
  • 免疫療法的類型
  • 檢查點抑制劑
  • 未滿足的醫療需求
  • 用於分層患者的新生物標誌物
  • 復發/難治性患者
  • 療效和耐受性
  • 創新策略
  • 新的目標方法
  • 單克隆抗體
  • 白介素
  • 干擾素

第4章市場動態

  • 免疫療法市場的優勢
  • 人口老齡化增加
  • 疾病發病率增加
  • 專利到期日期
  • 不斷增長的管道
  • 努力降低成本
  • 政府激勵措施
  • 合作與夥伴關係
  • 併購
  • 免疫療法市場的弱點
  • 製造過程
  • 流程定義,測試和確認
  • 缺乏熟練的人員
  • 監管準則
  • 專利程序
  • 對免疫療法市場的威脅
  • 不可預測的監管狀況
  • 從業者/藥房處方
  • 衝突
  • 免疫療法市場的機會
  • 新興市場
  • 技術創新和改進的工藝知識
  • 定價

第5章COVID-19對製藥行業的影響

  • 短期影響
  • 需求變化
  • 轉向遠程交互以進行溝通和推廣
  • 研發變更
  • 長期影響
  • 與COVID無關的藥物的延遲批准
  • 製藥業的自給自足
  • 與健康相關的產品的消費趨勢變化

第6章按產品類型細分的市場

  • 概述
  • 單克隆抗體
  • 市場概況
  • 市場收入
  • 市場份額
  • 區域市場
  • 市場概況
  • 市場收入
  • 市場份額
  • 檢查點抑制劑
  • 派姆單抗
  • 伴隨診斷
  • 臨床試驗計劃
  • 派姆單抗預測
  • Nivolumab(Opdivo)
  • 伴隨診斷
  • 臨床試驗計劃
  • Nivolumab預測
  • Atezolizumab(Tecentriq)
  • 伴隨診斷
  • 臨床試驗計劃
  • Atezolizumab預測
  • Avelumab(Bavencio)
  • 伴隨診斷
  • 臨床試驗計劃
  • 阿貝魯瑪的天氣預報
  • Durvalumab(英菲格)
  • 伴隨診斷
  • 臨床試驗計劃
  • Durvalumab預測
  • Yervoy(ipilimumab)
  • 區域市場
  • 市場收入
  • 市場份額
  • 干擾素和白介素
  • 市場收入
  • 區域市場
  • 按疾病領域劃分的市場

第7章按地區劃分的市場細分

  • 市場概述和考慮
  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 亞太地區
  • 中國
  • 日本
  • 其他地區

第8章公司簡介

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • VIATRIS INC. (FORMERLY MYLAN)
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.
目錄
Product Code: PHM249A

Highlights:

The global market for immunotherapy drugs should grow from $139.8 billion in 2020 to $204.4 billion by 2025, at compound annual growth rate (CAGR) of 7.9% for the period of 2020-2025.

The monoclonal antibodies product for immunotherapy drugs should grow from $113.2 billion in 2020 to $153.3 billion by 2025, at a CAGR of 6.3% for the period of 2020-2025.

The checkpoint inhibitors product for immunotherapy drugs should grow from $26.3 billion in 2020 to $50.9 billion by 2025, at a CAGR of 14.1% for the period of 2020-2025.

Report Scope:

The global immunotherapy market can be segmented into the following types: checkpoint inhibitors, monoclonal antibodies, interferons and interleukins. This report does not include other immunotherapies such as vaccines and hormones.

The scope of the report includes an overview of the global market and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.

The report discusses technological, regulatory and economic trends that are affecting the market. It also explains the major drivers and regional dynamics of the global market and current trends within the industry.

Regional analysis includes North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan and Rest of Asia-Pacific) and rest of the world (RoW).

Report Includes:

  • 20 data tables and 26 additional tables
  • An overview of the global market for immunotherapy drugs
  • Estimation of the market size and analyses of global market trends, with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) though 2025
  • Evaluation of current market size and forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
  • Description of immunotherapy, combination immunotherapy and discussion on how it targets on cell-mediated adaptive immunity
  • Market share analysis of the immunotherapy drugs based on type of drug, therapy area, end user and region
  • Information on personalized treatment paradigm, details of clinically significant types of cancers and discussion on future of immunotherapy in cancer
  • Details of checkpoint inhibitors, monoclonal antibodies, interleukins and interferons; and coverage of innovative strategies and novel targeted approaches for immunotherapy
  • Discussion on fine tuning versus boosting cancer immunity and early versus advanced stage cancer immunotherapy
  • Market share analysis of the major players in the industry, and discussion on their technological strengths and weakness, and innovative marketing practices
  • Comprehensive company profiles of major players of the industry, including Amgen Inc., Bayer AG, Johnson & Johnson, Novartis AG and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Scope of Report
  • Methodology
  • Market Estimates
  • Information Sources
  • Primary Research
  • Secondary Research
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Immunotherapy
  • Towards Combination Immunotherapy
  • Focusing on Cell-mediated Adaptive Immunity
  • Fine Tuning Vs. Boosting Cancer Immunity
  • Early Vs. Advanced Stage Cancer Immunotherapy
  • Personalized Treatment Paradigm
  • Clinically Significant Types of Cancers
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Leukemia
  • Future of Immunotherapy in Cancer
  • Infectious Diseases
  • Immunotherapy against Autoimmune Disorders
  • Immunotherapies against Infectious Diseases
  • Biologics as Autoimmune Disorder Therapies
  • Trends in Autoimmune Disorder Therapies
  • Types of Immunotherapies
  • Checkpoint Inhibitors
  • Unmet Medical Needs
  • New Biomarkers to Stratify Patients
  • Relapse/Refractory Patients
  • Treatment Efficacy and Tolerability
  • Innovative Strategies
  • Novel Targeted Approaches
  • Monoclonal Antibodies
  • Interleukins
  • Interferons

Chapter 4 Market Dynamics

  • Strengths of Immunotherapy Market
  • Growing Aging Population
  • Rising Incidence of Diseases
  • Patent Expirations
  • Growing Pipeline
  • Drive to Reduce Costs
  • Government Incentives
  • Collaborations and Partnerships
  • Mergers and Acquisitions
  • Weaknesses of the Immunotherapy Market
  • Manufacturing Process
  • Process Definition and Testing and Validation
  • Lack of Skilled Personnel
  • Regulatory Guidelines
  • Patent Litigation
  • Threats to Immunotherapy Market
  • Unpredictable Regulatory Landscape
  • Prescriptions by Medical Practitioners/Pharmacies
  • Competition
  • Opportunities in the Immunotherapy Market
  • Emerging Markets
  • Technological Innovation and Improved Process Knowledge
  • Pricing

Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry

  • Short-term Impact
  • Change in Demand
  • Shift of Communication and Promotions to Remote Interactions
  • Changes to R&D
  • Long-term Impact
  • Delayed Approvals for Non-COVID-related Pharmaceutical Products
  • Self-sufficiency in the Pharmaceutical Industry
  • Changes in Consumption Trends in Health-related Products

Chapter 6 Market Breakdown by Product Type

  • Overview
  • Monoclonal Antibodies
  • Market Overview
  • Market Revenue
  • Market Share
  • Market by Region
  • Market Overview
  • Market Revenue
  • Market Share
  • Checkpoint Inhibitors
  • Pembrolizumab
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Pembrolizumab
  • Nivolumab (Opdivo)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Nivolumab
  • Atezolizumab (Tecentriq)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Atezolizumab
  • Avelumab (Bavencio)
  • Companion Diagnostic
  • Clinical Trial Program
  • Forecast for Avelumab
  • Durvalumab (Imfinzi)
  • Companion Diagnostic
  • Clinical Trial Program
  • Durvalumab Forecasts
  • Yervoy (Ipilimumab)
  • Market by Region
  • Market Revenue
  • Market Share
  • Interferons and Interleukins
  • Market Revenue
  • Market by Region
  • Market by Disease Area

Chapter 7 Market Breakdown by Region

  • Market Overview and Discussion
  • North America
  • United States
  • Canada
  • Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of the World

Chapter 8 Company Profiles

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • VIATRIS INC. (FORMERLY MYLAN)
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.

List of Tables

  • Summary Table B : Global Market for Immunotherapy Drugs, by Region, Through 2025
  • Summary Table A : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 1 : Stages of Lung Cancer
  • Table 2 : Biologics as Autoimmune Disorder Therapies
  • Table 3 : Adverse Events Associated with Immune-Checkpoint Blockade
  • Table 4 : Evolution of Monoclonal Antibodies
  • Table 5 : Advantages and Disadvantages of Monoclonal Antibodies
  • Table 6 : Murine Monoclonal Antibodies
  • Table 7 : Chimeric Monoclonal Antibodies
  • Table 8 : Humanized Monoclonal Antibodies
  • Table 9 : Human Monoclonal Antibodies
  • Table 10 : Selected Approved Interferon Alpha Analogs
  • Table 11 : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 12 : Global Market for Monoclonal Antibodies, by Type, Through 2025
  • Table 13 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
  • Table 14 : Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
  • Table 15 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
  • Table 16 : Global Market for Checkpoint Inhibitors, 2019-2025
  • Table 17 : Pembrolizumab Approved Indications
  • Table 18 : Nivolumab Approved Indications
  • Table 19 : Atezolizumab Approved Indications
  • Table 20 : Avelumab Approved Indications
  • Table 21 : Durvalumab Approved Indications
  • Table 22 : Global Market of Checkpoint Inhibitors, by Region, Through 2025
  • Table 23 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
  • Table 24 : Global Market for Interferons and Interleukins, Through 2025
  • Table 25 : Global Market for Interferons and Interleukins, by Region, Through 2025
  • Table 26 : Global Market for Immunotherapy, by Therapeutic Area, Through 2025
  • Table 27 : Global Market for Immunotherapy Drugs, by Region, Through 2025
  • Table 28 : North American Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 29 : North American Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 30 : European Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 31 : European Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 32 : Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
  • Table 33 : Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
  • Table 34 : Chinese Market Statistics
  • Table 35 : Japanese Market Statistics
  • Table 36 : AbbVie: Product Portfolio
  • Table 37 : Amgen: Product Portfolio
  • Table 38 : AstraZeneca: Product Portfolio
  • Table 39 : Bayer AG: Product Portfolio
  • Table 40 : Johnson & Johnson: Product Portfolio
  • Table 41 : Viatris: Product Portfolio
  • Table 42 : Novartis AG: Product Portfolio
  • Table 43 : Pfizer: Product Portfolio
  • Table 44 : Pfizer: Pipeline Product Portfolio

List of Figures

  • Summary Figure A : Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
  • Summary Figure B : Global Market for Immunotherapy Drugs, by Region, 2019-2025
  • Figure 1 : Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
  • Figure 2 : Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
  • Figure 3 : Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
  • Figure 4 : Five-Year Survival Rates, by Lung Cancer Stage
  • Figure 5 : Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
  • Figure 6 : Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
  • Figure 7 : Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
  • Figure 8 : Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
  • Figure 9 : Five-Year Survival Rates, by Breast Cancer Stage
  • Figure 10 : Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
  • Figure 11 : Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
  • Figure 12 : Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
  • Figure 13 : Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
  • Figure 14 : Five-Year Survival Rates, by Colorectal Cancer Stage
  • Figure 15 : Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
  • Figure 16 : Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
  • Figure 17 : Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
  • Figure 18 : Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
  • Figure 19 : Five-Year Survival Rates, by Stomach Cancer Stage
  • Figure 20 : Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
  • Figure 21 : Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
  • Figure 22 : Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
  • Figure 23 : Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
  • Figure 24 : Potential Targets for Checkpoint Inhibition in Clinical Evaluation
  • Figure 25 : SWOT Analysis of Immunotherapy Market
  • Figure 26 : Impact of COVID-19 on the Pharmaceutical Industry
  • Figure 27 : Global Market for Immunotherapy Drugs, 2019-2025
  • Figure 28 : Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 29 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
  • Figure 30 : Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
  • Figure 31 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
  • Figure 32 : Pembrolizumab Comprehensive Clinical Trial Programs, by Status
  • Figure 33 : Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 34 : Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 35 : Global Market for Pembrolizumab, 2019-2025
  • Figure 36 : Nivolumab Comprehensive Clinical Trial Programs, by Status
  • Figure 37 : Nivolumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 38 : Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 39 : Global Market for Nivolumab, 2019-2025
  • Figure 40 : Atezolizumab Comprehensive Clinical Trial Programs, by Status
  • Figure 41 : Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 42 : Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 43 : Global Market for Atezolizumab, 2019-2025
  • Figure 44 : Avelumab Comprehensive Clinical Trial Programs, by Status
  • Figure 45 : Avelumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 46 : Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 47 : Global Market for Avelumab, 2019-2025
  • Figure 48 : Durvalumab Comprehensive Clinical Trial Programs, by Status
  • Figure 49 : Durvalumab Comprehensive Clinical Trial Programs, by Therapy
  • Figure 50 : Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
  • Figure 51 : Global Market for Durvalumab, 2019-2025
  • Figure 52 : Global Market for Ipilimumab, 2019-2025
  • Figure 53 : Global Market for Checkpoint Inhibitors, by Region, 2019-2025
  • Figure 54 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
  • Figure 55 : Global Market for Interferons and Interleukins, by Region, 2019-2025
  • Figure 56 : Global Market Shares for Immunotherapy Drugs, by Region, 2019
  • Figure 57 : North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 58 : European Market for Immunotherapy Drugs, by Country, 2019-2025
  • Figure 59 : European Market for Immunotherapy Drugs, by Product Type, 2019-2025
  • Figure 60 : Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
  • Figure 61 : AbbVie Inc.: Annual Revenue, 2016-2019
  • Figure 62 : AbbVie: Revenue Share, by Region/Country, 2019
  • Figure 63 : AbbVie: Revenue Share, by Business Unit, 2019
  • Figure 64 : Amgen: Annual Revenue, 2016-2019
  • Figure 65 : Amgen: Revenue Share, by Region/Country, 2019
  • Figure 66 : Amgen: Revenue Share, by Products, 2019
  • Figure 67 : AstraZeneca: Annual Revenue, 2016-2019
  • Figure 68 : AstraZeneca: Revenue Share, by Region/Country, 2019
  • Figure 69 : AstraZeneca: Revenue Share, by Business Unit, 2019
  • Figure 70 : Bayer AG: Annual Revenue, 2016-2019
  • Figure 71 : Bayer AG: Revenue Share, by Region, 2019
  • Figure 72 : Bayer AG: Revenue Share, by Business Unit, 2019
  • Figure 73 : Bristol Myers Squibb: Annual Revenue, 2016-2019
  • Figure 74 : Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
  • Figure 75 : Bristol Myers Squibb: Revenue Share, by Brands, 2019
  • Figure 76 : Hoffmann-La Roche: Annual Revenue, 2016-2019
  • Figure 77 : Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
  • Figure 78 : Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
  • Figure 79 : Johnson & Johnson: Annual Revenue, 2016-2019
  • Figure 80 : Johnson & Johnson: Revenue Share, by Region/Country, 2019
  • Figure 81 : Johnson & Johnson: Revenue Share, by Business Unit, 2019
  • Figure 82 : Viatris: Annual Revenue, 2016-2019
  • Figure 83 : Viatris: Revenue Share, by Region, 2019
  • Figure 84 : Viatris: Revenue Share, by Business Unit, 2019
  • Figure 85 : Novartis AG: Annual Revenue, 2015-2019
  • Figure 86 : Novartis AG: Revenue Share, by Region/Country, 2019
  • Figure 87 : Novartis AG: Revenue Share, by Business Segment, 2019
  • Figure 88 : Pfizer: Annual Revenue, 2016-2019
  • Figure 89 : Pfizer: Revenue Share, by Region/Country, 2019
  • Figure 90 : Pfizer: Revenue Share, by Business Segment, 2019
  • Figure 91 : Vertex Pharmaceuticals: Annual Revenue, 2016-2019
  • Figure 92 : Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
  • Figure 93 : Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019